• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»metabolic dysfunction-associated steatohepatitis

Why MetaVia’s higher-dose titration strategy could matter more than the first-patient milestone itself

By Pallavi Madhiraju on April 11, 2026   Pharma & Biotech  

Why MetaVia’s higher-dose titration strategy could matter more than the first-patient milestone itself

MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.

Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH

By Pallavi Madhiraju on February 20, 2026   Pharma & Biotech  

Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH

Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.

How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat

By Soujanya Ravi on January 9, 2026   Pharma & Biotech  

How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat

Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.

Recent Posts

  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
  • Can Covalon Technologies convert IV contamination education into adoption of VALGuard and CovaClear?
  • How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
  • CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes